Fewer Treatment Failures
Strategic drug-gene matching reduces trial-and-error approaches, improving disease control and patient quality of life.
Lower Adverse Events
Genetic insights guide dosing to minimize liver toxicity, allergic reactions, and other side effects often associated with DMARDs or biologics.
Improved Care Coordination
Rheumatologists, pharmacists, and primary care providers can easily collaborate via shared PGx data, streamlining treatment decisions.
Enhanced Value-Based Metrics
By reducing hospital admissions, ER visits, and chronic flare-ups, health systems see improved patient satisfaction and potential reimbursement gains.